Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Teva Pharmaceutical Industries ADR
(NY:
TEVA
)
13.81
+0.56 (+4.23%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Teva Pharmaceutical Industries ADR
< Previous
1
2
3
4
5
6
Next >
Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023
April 14, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Complete Response Letter Received for AVT02 Biologics License Application
April 13, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual Meeting
April 11, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva’s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U.S. Health System
March 27, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Early Settlement
March 13, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
March 09, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
March 09, 2023
By Julian Richard, Benzinga
Via
TheNewswire.com
Teva to Present at the Barclays Global Healthcare Conference
March 07, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Senior Notes and the Increase of the Maximum Tender Amount of its Debt Tender Offer
March 01, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026
February 27, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Launch of $2,060,000,000 (Equivalent) Offering of Sustainability-Linked Senior Notes
February 27, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting
February 24, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact of Tardive Dyskinesia on Patients’ Lives
February 23, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets
February 17, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reaches Agreement With Florida to Settle the State’s Price Fixing Claims
February 09, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reports Fourth Quarter and Full Year 2022 Financial Results
February 08, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva’s Ambitious Climate Targets Externally Validated by the Science Based Targets initiative (SBTi)
January 19, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and 2023 Financial Guidance at 8 a.m. ET on February 8, 2023
January 12, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Nationwide Opioids Settlement to Move Forward After Receiving Broad Support from States
January 09, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
January 06, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
January 06, 2023
From
Alvotech
Via
GlobeNewswire
Teva to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®
December 22, 2022
From
Alvotech
Via
GlobeNewswire
Teva Finalizes Nationwide Opioid Settlement Terms
November 22, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Appointment of Richard Francis as President and CEO
November 21, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Unique Collaboration with Rimidi to Expand the Reach of its Respiratory Digital Health Platform
November 14, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Unique Collaboration with HealthSnap to Expand the Reach of its Respiratory Digital Health Platform
November 14, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present Latest Research from the CONNECT1 and CONNECT2 Clinical Trials at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific Meeting
November 07, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reports Third Quarter 2022 Financial Results
November 03, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Clinics Across Florida, New Jersey & California Advancing Mental Health in Underserved Communities – Awarded Funding from Teva Pharmaceuticals, Direct Relief and NAFC
October 25, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.